Table 2.
Summary of lipid nanoparticle composition, lipid size and encapsulation efficiency from evidence sources
| Ref. | Ocular disease | Target cell type | Formulation of LNP | Size, nm | Type of nucleic acid encapsulated | EE (%) |
|---|---|---|---|---|---|---|
| [30] | Inherited retinal degenerations specific to RPE | Retinal pigment epithelium (RPE) cells | Microfluidic mixing of MC3 | 148 ± 68.4 | mRNA | 97.9 |
| Microfluidic mixing of KC3 4 | 115 ± 33.4 | mRNA | 97.1 | |||
| Microfluidic mixing of DODMA | 82. 8 ± 27.3 | mRNA | 95.2 | |||
| [31] | Retinoblastoma | Retinoblastoma cells, both primary and Y-79 lineage. | pH-sensitive cationic lipids/DSPC/cholesterol/DSPE-PEG2000 | 171 ± 4 | miR-181a | 93.0 ± 0.2 (Melafalan) and 97.5 ± 0.7 (miR-181a) |
| [32] | Retinal degeneration and glaucoma | RPE cells | Microfluidic mixing of MC3, DSPC, DMG-PEG2k and cholesterol in a molar ratio of 50:10:0.5:0.5:39.5 | 150 | mRNA | 97.8 |
| Microfluidic mixing of MC3, DSPC, DMG-PEG2k and cholesterol in a molar ratio of 50:10:1.5:38.5. | 150 | mRNA | 96.2 | |||
| [33] | Corneal dystrophies | Corneal layer cells | DOPE, cationic lipids and cholesterol 60:30:10 | 397 ± 44 | siRNA | 97 |
| [34] | Glaucoma, age-related macular degeneration | Stable cells (HEK293-GFP) or GFP293 cells and primary retinal ganglion cells | DOTAP, DOPE, CHOL and DSPE-PEG2000. Molar ratios 40:23:25:10:2 | 75 | siRNA | 99 |
| [35] | Ocular fibrosis | Human conjunctival fibroblast |
LNP-MRTF-B siRNA CL4H6, DOPE and PEG-DMG |
214.4 ± 2.6 | siRNA | 92.5 ± 0.7 |
|
LNP + cY-MRTF-B siRNA CL4H6, DOPE and PEG |
211.1 ± 1.9 | siRNA | 99.3 ± 0.1 |